Eleven Biotherapeutics Inc. (EBIO) Stock Price Down 3.9%
Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) were down 3.9% during mid-day trading on Wednesday . The company traded as low as $3.85 and last traded at $3.98, with a volume of 1,784,210 shares traded. The stock had previously closed at $4.14.
The stock has a 50 day moving average price of $2.83 and a 200-day moving average price of $1.29. The company’s market capitalization is $62.03 million.
In other Eleven Biotherapeutics news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the business’s stock in a transaction on Monday, June 13th. The shares were sold at an average price of $2.74, for a total transaction of $2,855,080.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.